Download MendeleyHuman neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2.
Bianchini, F., Crivelli, V., Abernathy, M.E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., Gasparo, R., Simonelli, L., Matkovic, M., Toscano, C., Biggiogero, M., Calvaruso, V., Svoboda, P., Rincon, T.C., Fava, T., Podesvova, L., Shanbhag, A.A., Celoria, A., Sgrignani, J., Stefanik, M., Honig, V., Pranclova, V., Michalcikova, T., Prochazka, J., Guerrini, G., Mehn, D., Ciabattini, A., Abolhassani, H., Jarrossay, D., Uguccioni, M., Medaglini, D., Pan-Hammarstrom, Q., Calzolai, L., Fernandez, D., Baldanti, F., Franzetti-Pellanda, A., Garzoni, C., Sedlacek, R., Ruzek, D., Varani, L., Cavalli, A., Barnes, C.O., Robbiani, D.F.(2022) Biorxiv
- PubMed: 36482967
- DOI: 10.1101/2022.11.24.515932
- Primary Citation of Related Structures:
8D47, 8D48 - PubMed Abstract:
Emergence of SARS-CoV-2 variants diminishes the efficacy of vaccines and antiviral monoclonal antibodies. Continued development of immunotherapies and vaccine immunogens resilient to viral evolution is therefore necessary. Using coldspot-guided antibody discovery, a screening approach that focuses on portions of the virus spike that are both functionally relevant and averse to change, we identified human neutralizing antibodies to highly conserved viral epitopes ...
